Risk Evaluation and Mitigation Strategies for some Rx drugs

November 2010

You'll hear lots more about "REMS" as FDA phases in their new Risk Evaluation and Mitigation Strategies for some Rx drugs....

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology whether dabigatran (Pradaxa) will replace warfarin for patients with atrial fibrillation
Gout lots of ads for new gout drugs...Uloric, Colcrys, and now Krystexxa
Asthma Spiriva (TIOtropium) used in some adults with asthma
Psychiatry New guidelines say to select antidepressants based on side effects, other medical conditions, drug interactions, and cost
Vaccines More adults are now candidates for pneumococcal vaccination
Gastroenterology whether sodium polystyrene sulfonate (Kayexalate, etc) is safe for hyperkalemia
Obesity & Weight Loss what to do now that the weight loss drug Meridia (sibutramine) is gone
Pediatrics Up to 15% of babies and toddlers don't get enough iron
Substance Use Disorder People are abusing some unexpected OTC and Rx meds
You'll hear more about cardiovascular risk calculators
Risk Evaluation and Mitigation Strategies for some Rx drugs